Johnson & Johnson (NYSE:JNJ) Shares Acquired by Dohj LLC

Dohj LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 19.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,291 shares of the company’s stock after purchasing an additional 2,347 shares during the quarter. Dohj LLC’s holdings in Johnson & Johnson were worth $2,370,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in JNJ. Norges Bank acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $4,390,037,000. Raymond James Financial Inc. acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $1,339,878,000. GAMMA Investing LLC boosted its position in shares of Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company’s stock valued at $1,196,596,000 after purchasing an additional 7,185,977 shares during the period. Janus Henderson Group PLC boosted its position in shares of Johnson & Johnson by 134.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company’s stock valued at $1,149,536,000 after purchasing an additional 4,559,147 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Johnson & Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company’s stock valued at $4,456,201,000 after purchasing an additional 3,363,235 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

JNJ has been the subject of a number of research analyst reports. Benchmark raised Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. The Goldman Sachs Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Morgan Stanley increased their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 16th. Raymond James decreased their price objective on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research report on Monday, April 14th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday, June 5th. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $170.88.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $156.90 on Friday. The company has a market cap of $377.52 billion, a price-to-earnings ratio of 23.59, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The stock has a 50 day simple moving average of $153.84 and a 200-day simple moving average of $153.71. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were paid a $1.30 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.31%. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.